This includes the creation, in collaboration with leading United States institutions, of three major programmes aimed at development of molecular diagnostics: the Integrated BioBank of Luxembourg, the Luxembourg Centre for Systems Biomedicine, and a pilot programme to find and validate biomarkers for use in disease management and therapeutic follow-up in lung cancer. In 2010 these and a number of other research programmes were brought together to create the Personalized Medicine Consortium to co-ordinate and support research in the areas of cancer, type 2 diabetes and Parkinson’s disease. Respondents also mentioned that commercial development in the area of molecular diagnostics is also promoted through the Luxembourg BioHealth Cluster.